Precigen Secures Seven-Year U.S. Orphan Drug Exclusivity for PAPZIMEOS Through 2032
PGEN•FDA granted a seven-year orphan drug exclusivity for PAPZIMEOS through August 14, 2032, for adults with recurrent respiratory papillomatosis, securing U.S. market protection. PAPZIMEOS, first and only FDA-approved RRP therapy since August 2025, is commercially available nationwide to an estimated 27,000 adult patients.
1. Orphan Drug Exclusivity Granted
The FDA has granted orphan drug exclusivity for PAPZIMEOS in adult recurrent respiratory papillomatosis, effective August 14, 2025 through August 14, 2032, providing seven years of U.S. market protection.
2. First and Only Approved RRP Therapy
PAPZIMEOS received full FDA approval in August 2025 as the first and only approved therapy targeting the root cause of RRP and is now commercially available across major medical centers and community practices nationwide.
3. Defined Addressable Market
An internal analysis of claims and electronic health records estimates approximately 27,000 adult RRP patients in the U.S. are eligible for PAPZIMEOS treatment, indicating a clear opportunity for revenue generation.
4. Enhanced Market Protection
This orphan drug exclusivity, paired with Precigen’s patent portfolio covering PAPZIMEOS and its therapeutic use, strengthens barriers to entry and bolsters long-term revenue potential for the company.
